ConductScience.org, home

Paper7586898

Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.

Stretcher BN. Clin Pharmacokinet, 1995. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Papers, record 7586898. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7586898

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection.
PubMed
Journal
Clin Pharmacokinet
PubMed
Year
1995
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
0.51
iCite
Revised in PubMed
2026-10-11
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Stretcher BNB N

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antiviral AgentsMajor topic
HIV InfectionsMajor topic
Aging
Antineoplastic Agents
Didanosine
Drug Interactions
Guidelines as Topic
Humans
Phosphorylation
Racial Groups
Sex Characteristics
Stavudine
Zalcitabine
Zidovudine

Source PubMed

Download CSV of topics

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00000965The Effects of Zidovudine on the Blood of HIV-Infected PatientsBackground

Source ClinicalTrials.gov

Download CSV of trials

References128

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
18175673Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2',3'-dideoxynucleoside analogs in resting and activated human cells.J Biol Chem1994https://conductscience.org/library/papers/8175673PubMed
22570186Probenecid and zidovudine metabolism.Lancet1989https://conductscience.org/library/papers/2570186PubMed
31988507Pharmacokinetic disposition of zidovudine during pregnancy.J Infect Dis1991https://conductscience.org/library/papers/1988507PubMed
48097711Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.Drug Metab Dispos1993https://conductscience.org/library/papers/8097711PubMed
52663302Clinical pharmacokinetics of zidovudine. An overview of current data.Clin Pharmacokinet1989https://conductscience.org/library/papers/2663302PubMed
61895207Canadian multicenter azidothymidine trial: AZT pharmacokinetics.J Acquir Immune Defic Syndr (1988)1991https://conductscience.org/library/papers/1895207PubMed
71510405Ganciclovir antagonizes the anti-human immunodeficiency virus type 1 activity of zidovudine and didanosine in vitro.Antimicrob Agents Chemother1992https://conductscience.org/library/papers/1510405PubMed
81492005Comparative pharmacokinetics of zidovudine in healthy volunteers and in patients with AIDS with and without hepatic disease.Pharmacotherapy1992https://conductscience.org/library/papers/1492005PubMed
98366182Effect of time of food administration on the bioavailability of didanosine from a chewable tablet formulation.J Clin Pharmacol1993https://conductscience.org/library/papers/8366182PubMed
101346807The effect of zidovudine treatment on serum neopterin and beta 2-microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals.J Acquir Immune Defic Syndr (1988)1992https://conductscience.org/library/papers/1346807PubMed
111328267High-performance liquid chromatographic determination of 2',3'-didehydro-3'-deoxythymidine, a new anti-human immunodeficiency virus agent, in human plasma and urine.J Chromatogr1992https://conductscience.org/library/papers/1328267PubMed
128096373CD4+ lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine.Ann Intern Med1993https://conductscience.org/library/papers/8096373PubMed
138254464Evidence of in vitro development of drug resistance to azidothymidine in T-lymphocytic leukemia cell lines (Jurkat E6-1/AZT-100) and in pediatric patients with HIV-1 infection.J Acquir Immune Defic Syndr (1988)1993https://conductscience.org/library/papers/8254464PubMed
141720152Detection of mutations associated with zidovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction.J Infect Dis1991https://conductscience.org/library/papers/1720152PubMed
151686178The association of clinical conditions and serologic tests with CD4+ lymphocyte counts in HIV-infected subjects without AIDS.AIDS1991https://conductscience.org/library/papers/1686178PubMed
162293412In vitro measurement of phosphorylated zidovudine in peripheral blood leucocytes.Ther Drug Monit1990https://conductscience.org/library/papers/2293412PubMed
171379914Didanosine. A review of its antiviral activity, pharmacokinetic properties and therapeutic potential in human immunodeficiency virus infection.Drugs1992https://conductscience.org/library/papers/1379914PubMed
182159302Cellular pharmacology of 2',3'-didehydro-2',3'-dideoxythymidine (D4T) in human peripheral blood mononuclear cells.Biochem Pharmacol1990https://conductscience.org/library/papers/2159302PubMed
192053945A reduced dose of zidovudine in patients with AIDS.N Engl J Med1991https://conductscience.org/library/papers/2053945PubMed
201671651Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine.BMJ1991https://conductscience.org/library/papers/1671651PubMed

See all 128 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
17694300Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.Eur J Clin Pharmacol2007https://conductscience.org/library/papers/17694300PubMed
17638393Nucleoside and nucleotide reverse transcriptase inhibitors in children.Clin Drug Investig2007https://conductscience.org/library/papers/17638393PubMed
16122281Pharmacokinetics of antiretroviral therapy in HIV-1-infected children.Clin Pharmacokinet2005https://conductscience.org/library/papers/16122281PubMed
9100148AIDS clinical trials. Is there access for all?J Gen Intern Med1997https://conductscience.org/library/papers/9100148PubMed
8861550Stavudine: a review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection.Drugs1996https://conductscience.org/library/papers/8861550PubMed
8743337Drug interactions with antiviral drugs.Clin Pharmacokinet1996https://conductscience.org/library/papers/8743337PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7586898

GET https://conductscience.org/api/papers/v1/7586898/references?page=2